PMID- 19950698
OWN - NLM
STAT- MEDLINE
DCOM- 20101021
LR  - 20121115
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 31
IP  - 7
DP  - 2009 Jul
TI  - [Detection and clinical significance of JAK2 mutation in 412 patients with 
      chronic myeloproliferative neoplasms].
PG  - 510-4
AB  - OBJECTIVE: To investigate the frequency of JAK2V617F mutation in Chinese patients 
      with chronic myeloproliferative neoplasms (MPN) and to study the relationship 
      between JAK2V617F mutation and clinical characteristics. METHODS: JAK2V617F 
      mutation was screened by allele-specific polymerase chain reaction (AS-PCR). 
      RESULTS: JAK2V617F mutation was detected in 277 of the 412 patients with MPN. The 
      frequency of JAK2V617F mutation was similar among essential thrombocythemia (ET), 
      idiopathic myelofibrosis (IMF) and chronic myeloproliferative 
      disorders-unclassified (MPD-U) (P > 0.05), but it was significantly lower than 
      that in polycythemia vera (PV) (P < 0.05). The presence of JAK2V617F was found to 
      be significantly correlative with advanced age at diagnosis (P < 0.01) and with 
      higher hemoglobin levels and higher leukocyte counts (P < 0.05). Significant 
      difference was found in complication of vascular events between JAK2V617 positive 
      and negative patients (P < 0.05). JAK2V617F positive MPD-U patients were more 
      prone to progress into typical MPN compared with JAK2V617F negative MPD-U 
      patients. The association between abnormal karyotype and JAK2V617F was not found 
      in cytogenetical analysis of 301 patients. CONCLUSION: The presence of JAK2V617F 
      in MPD-U is associated with the disease development. There is a correlation 
      between JAK2V617F mutation in MPN and advanced age, higher leukocyte counts, 
      hemoglobin level and vascular events.
FAU - Chao, Hong-Ying
AU  - Chao HY
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Insititute of 
      Hematology, Suzhou 215006, China.
FAU - Fan, Zheng
AU  - Fan Z
FAU - Zhang, Ri
AU  - Zhang R
FAU - Shen, Yi-Min
AU  - Shen YM
FAU - Chen, Wan
AU  - Chen W
FAU - Fei, Hai-Rong
AU  - Fei HR
FAU - Zhu, Zi-Ling
AU  - Zhu ZL
FAU - Feng, Yu-Feng
AU  - Feng YF
FAU - Chen, Zi-Xing
AU  - Chen ZX
FAU - Xue, Yong-Quan
AU  - Xue YQ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (Hemoglobins)
RN  - EC 2.7.10.2 (Janus Kinase 2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Follow-Up Studies
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Janus Kinase 2/*genetics
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Myeloproliferative Disorders/blood/complications/*genetics
MH  - Polycythemia Vera/blood/complications/genetics
MH  - Primary Myelofibrosis/blood/complications/genetics
MH  - Thrombocythemia, Essential/blood/complications/genetics
MH  - Thrombosis/etiology
MH  - Young Adult
EDAT- 2009/12/03 06:00
MHDA- 2010/10/22 06:00
CRDT- 2009/12/03 06:00
PHST- 2009/12/03 06:00 [entrez]
PHST- 2009/12/03 06:00 [pubmed]
PHST- 2010/10/22 06:00 [medline]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):510-4.